Jefferies & Co Downgrades ResMed (RMD) to Hold
More News related to RMD
- Notable Analyst Rating Changes 11/06: GE, CBS, HD/LOW, M Upgrade; ESLR, RMD, SUN Downgrade
- Morgan Stanley Downgrades ResMed (RMD) to Equalweight
- Jefferies & Co Downgrades ResMed (RMD) to Hold
- ResMed (RMD) Tops Q3 Views
- ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009
More News related to Downgrades
- KeyBanc Initiates Coverage on Tiffany & Co. (TIF) with a Buy; Share Gains, Gross Margin Increase
- Collins Stewart Initiates Coverage on Expedia (EXPE) with a Buy
- Janney Montgomery Scott Initiates Coverage on Northwest Natural Gas (NWN) with a Neutral
- Traders Cheer Morgan Stanley's New Overweight Rating on AmEx (AXP)
- CL King Initiates Coverage on Schiff Nutrition International (WNI) with a Strong Buy
Jefferies & Co downgrades ResMed (NYSE: RMD) from Buy to Hold. Price target increased from $50 to $53.
To see more analyst ratings on RMD Click Here.
ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
Related Categories
DowngradesStocks Mentioned
+0.22Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
